Omeros Corp. (OMER) PT Lowered to $22 at Needham & Company Following 4Q Report; 'OMS721 Ph3 Trial Now Underway'

March 17, 2017 6:24 AM

Needham & Company analyst Serge Belanger lowered its price target on Omeros Corp. (NASDAQ: OMER) to $22.00 (from $24.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found